Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.65 |
| ▸ | ANPEP | P15144 | 4/20 | 0.65 |
| ▸ | LAP3 | P28838 | 6/20 | 0.61 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.61 |
| ▸ | CPA3 | P15088 | 3/20 | 0.59 |
| ▸ | CPA1 | P15085 | 2/20 | 0.59 |
| ▸ | CPB1 | P15086 | 1/20 | 0.59 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7367028 | 0.86 | FOLH1 (0.55) | FOLH1CYP1A2ERAP2ANPEP | |
| SCHEMBL9068560 | 0.86 | CYP1A2 (0.63) | FOLH1CYP1A2ERAP2ANPEPLAP3 | |
| SCHEMBL5058107 | 0.84 | CYP1A2 (0.61) | FOLH1CYP1A2ERAP2ANPEPLAP3 | |
| SCHEMBL30861830 | 0.82 | FOLH1 (0.70) | FOLH1CYP1A2ERAP2ANPEPLAP3 | |
| SCHEMBL29182376 | 0.82 | FOLH1 (0.70) | FOLH1CYP1A2ERAP2ANPEPLAP3 | |
| SCHEMBL7440491 | 0.82 | FOLH1 (0.51) | FOLH1CYP1A2ERAP2ANPEP | |
| SCHEMBL5051239 | 0.82 | ERAP1 (0.58) | FOLH1ERAP2ANPEPLAP3ERAP1 | |
| SCHEMBL4664822 | 0.82 | CYP1A2 (1.00) | FOLH1CYP1A2CPA3CPA1CPB1 | |
| SCHEMBL7361954 | 0.81 | SLC1A3 (0.59) | FOLH1CYP1A2ERAP2ANPEPLAP3 | |
| SCHEMBL9696151 | 0.80 | ANPEP (0.72) | ERAP2ANPEPLAP3ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-6054444-A | INHIBIT N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-25 | — | — | US | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1998047906-A1 | PHOSPHONIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-29 | — | — | WO | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| US-6288046-B1 | ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE/N-/ INHIBITORS; CARBOXYALKYLPHOSPHATES; PROSTATE DISORDERS; GLUTAMATE ABNORMALITIES; NERVOUS SYSTEM DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-09-11 | — | — | US | disclosed |
| US-6054444-A | INHIBIT N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-25 | — | — | US | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998047906-A1 | PHOSPHONIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | FOLH1 56/4885CYP1A2 4200/4885ERAP2 494/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885CYP1A2 4283/4885ERAP2 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.